Safety and Efficacy of Combined Yttrium 90 Resin Radioembolization with Aflibercept and FOLFIRI in a Patient with Metastatic Colorectal Cancer

Table 1

Chronologic assessment and therapy of patient.

Date	Chemotherapy	Biologic therapy	Y90 treatment	Chest CT	Abdomen CT	Abdominal MRI
06/07/13	—	—	—	Lung mass in the right lower lobe	Multiple liver lesions	—
06/17/13	FOLFIRI	Aflibercept	—	—	—	—
07/03/13	—	—	Right lobe radio embolization	—	—	—
7/15/13	FOLFIRI	Held due to risk of bleeding from radioembolization	—	—	—	—
08/08/13	—	—	Right and left lobe radio embolization	—	—	—
08/19/13	FOLFIRI	Aflibercept resumed	—	—	—	—
09/02/13	FOLFIRI	Aflibercept	—	—	—	—
09/20/13	FOLFIRI	Aflibercept	—	Stable; pulmonary nodules	Stable liver hypodensities	Interval decrease in size of the hepatic masses in the right lobe of the liver
10/07/13	FOLFIRI	Aflibercept	—	—	—	—
10/21/13	Omission of 5-FU due to fatigue and dehydration but continued with irinotecan	Aflibercept	—	—	—; —	—; —
11/18/13	Irinotecan	Aflibercept held due to worsening fatigue	—	—	—	—
11/25/13	Irinotecan	Held Aflibercept due to fatigue	—	—	—	—
12/2/13	Irinotecan	Aflibercept resumed at 50% reduced dose	—	—	—	—
12/16/13	Irinotecan	Aflibercept continued at 50% reduced dose	—	—	—	—
12/30/13	Chemotherapy held due to G3 fatigue and G3 diarrhea	Chemotherapy held due to G3 fatigue and G3 diarrhea	—	Interval increase of lung nodules (Progression)	Stable disease within the liver, interval development of small abdominal ascites (from trace on prior imaging) and slightly nodular contour to the liver, reflecting treatment related effects of prior radioembolization and chemotherapy.	—
1/21/14	Started on a phase I study with a novel anti-VEGFR3 antibody	—	—	—	—	—